Also, PSMA-targeting radioligand therapy, although traditionally used in prostate cancer, has been explored for brain tumors via intra-arterial administration, including meningiomas, where PSMA is expressed in tumor-associated vasculature. This evidence concerns the gene FOLH1 and prostate cancer.